Navigation Links
ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
Date:6/30/2008

t Phase IIa clinical trial of patients suffering from post-herpetic neuralgia. In this study, ELADUR showed improved pain control versus placebo during the 3-day continuous treatment period. In addition, ELADUR appeared to be well tolerated overall, and patients treated with ELADUR and placebo exhibited similar safety profiles. A poster describing this study was presented at the 27th Annual Scientific Meeting of the American Pain Society on May 8, 2008 and is accessible on our website (http://www.durect.com/wt/durect/page_name/Publications).

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including Remoxy(TM), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit http://www.durect.com.

NOTE: ORADUR(TM), POSIDUR(TM), ELADUR(TM) and TRANSDUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. Remoxy, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding ELADUR, its anticipated attributes and commercial potential, its potential to be a best in class transdermal product for those suffering from PHN and its potential to receive seven years of market exclusivity as an orphan drug are forward-looking statements
'/>"/>

SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
3. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
4. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
5. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
6. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
9. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
10. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
11. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- CVS Caremark (NYSE: CVS ) announced today ... MedStar Health, a leading health care system with ten ... Washington, DC , region, which will ... patients. Through this clinical affiliation, MedStar Health patients will ... chronic disease monitoring and wellness programs at CVS/pharmacy stores ...
(Date:8/27/2014)... and NINGBO, China , Aug. ... Ningbo Menovo Pharmaceutical Co., Ltd, ("Menovo") today announced they ... of generic pharmaceuticals, primarily targeting the United ... agreement, Amerigen and Menovo will jointly develop products for ... . Menovo will be responsible for manufacturing API ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty Liver ... on the Fatty Liver Disease clinical trial scenario. This ... clinical trials on Fatty Liver Disease . It ... recruitment status as per the site of trial conduction ... of disease clinical trials by their phase, trial status, ...
Breaking Medicine Technology:CVS Caremark Announces New Clinical Affiliation with MedStar Health 2CVS Caremark Announces New Clinical Affiliation with MedStar Health 3Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5
... Genomma Lab Internacional, S.A.B. de C.V. (BMV: ... for the quarter ended September 30, 2009. All figures ... are stated in nominal Mexican pesos. Also, the following consolidated ... according to Mexican GAAP. , 3Q09 Highlights (vs. 3Q08) ...
... Beckman Coulter, Inc. (NYSE: BEC ), a leading developer, ... complex biomedical testing, announced today that the company will present ... Conference - Wednesday, November 4, 2009 at 3:20 p.m. ET ... at 11:00 a.m. ET , The live webcast ...
Cached Medicine Technology:Genomma Lab Internacional Announces Third Quarter 2009 Results 2Genomma Lab Internacional Announces Third Quarter 2009 Results 3
(Date:8/27/2014)... News) -- Health care workers in poor nations often ... safe from being infected with blood-borne viruses such as ... the study was conducted before the current Ebola outbreak ... confirmed in statistics released Monday by the World Health ... an "unprecedented" number of health care workers have lost ...
(Date:8/27/2014)... the second leading cause of cancer-associated death worldwide. ... difficulty in treating this cancer using conventional chemotherapeutic ... or combinations therein. This may be attributed to ... reach in a sufficient concentration in the liver ... to the rest of the body. Considering the ...
(Date:8/27/2014)... portions a week of tomatoes have an 18 per ... suggests. , With 35,000 new cases every year in ... the second most common cancer in men worldwide. , ... believe is linked to a Westernised diet and lifestyle. ... reduces risk of prostate cancer, researchers at the Universities ...
(Date:8/27/2014)... Catalent, the leading global provider of ... biologics and consumer health products, today announced that ... research company, Minomic International Limited, to develop MIL-38, ... therapy. Under the agreement, Catalent will initially produce ... view to larger scale production subject to a ...
(Date:8/27/2014)... When a friend invited Misty Mozejko to join ... was the beginning of a new way of life and a ... Misty. “I knew I needed to turn my life around but ... been, Misty stuck with the program. “It was so difficult,” she ... of my comfort zone, but between the boot camp and some ...
Breaking Medicine News(10 mins):Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 2Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 3Health News:The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment 2Health News:The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment 3Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Catalent and Minomic Collaborate to Bring New Prostate Cancer Treatment to Market 2Health News:Catalent and Minomic Collaborate to Bring New Prostate Cancer Treatment to Market 3Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 2Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 3
... ... Safety and Telemedicine solutions provider MainStreet Monitoring Devices selects SensorLogic’s asset tracking Cloud ... systems that advance the care and protection of children and seniors, including individuals ... ...
... ... Management Services for their Clients. , ... Buffalo, NY (Vocus) March 3, 2010 -- IVR Technology Group today announced ... call-tracking services to provide midsize and large market clients with state of the art Interactive ...
... ... a Philadelphia area-based non-profit started after an amazing bicycle trek across Europe that took place ... to Warsaw, Poland in an effort to raise world awareness and funds for a group ... ...
... ... ... ... ...
... , ... ... ... ...
... ... ... , ... ...
Cached Medicine News:Health News:MainStreet MD Launches Personal Safety Solutions for Children and Seniors Built On SensorLogic's Cloud Computing Platform 2Health News:MainStreet MD Launches Personal Safety Solutions for Children and Seniors Built On SensorLogic's Cloud Computing Platform 3Health News:MainStreet MD Launches Personal Safety Solutions for Children and Seniors Built On SensorLogic's Cloud Computing Platform 4Health News:BASIC, a HR Service Company Expands Absence Management Services with IVR Technology Group 2Health News:BASIC, a HR Service Company Expands Absence Management Services with IVR Technology Group 3Health News:A Small Grass-roots Non-profit, Announces That They Haven't Gone Away and are Still Alive with Helping the Disadvantaged Children in Ukraine 2Health News:A Small Grass-roots Non-profit, Announces That They Haven't Gone Away and are Still Alive with Helping the Disadvantaged Children in Ukraine 3Health News:A Small Grass-roots Non-profit, Announces That They Haven't Gone Away and are Still Alive with Helping the Disadvantaged Children in Ukraine 4Health News:A Small Grass-roots Non-profit, Announces That They Haven't Gone Away and are Still Alive with Helping the Disadvantaged Children in Ukraine 5Health News:FDA Survey Finds More Americans Read Information on Food Labels 2Health News:FDA Survey Finds More Americans Read Information on Food Labels 3Health News:FDA Survey Finds More Americans Read Information on Food Labels 4Health News:FDA Survey Finds More Americans Read Information on Food Labels 5Health News:Pelosi Remarks at Press Availability on Health Insurance Reform 2Health News:Pelosi Remarks at Press Availability on Health Insurance Reform 3Health News:Pelosi Remarks at Press Availability on Health Insurance Reform 4Health News:Pelosi Remarks at Press Availability on Health Insurance Reform 5Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 2Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 3Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 4Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 5Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 6Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 7Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 8Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 9Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 10Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 11Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 12